(Q39195628)

English

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multip

scientific article published on 8 May 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multip (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

phase III clinical trial

0 references

0 references

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

Frederik Barkhof

1

object named as

Frederik Barkhof

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

author name string

Remko de Jong

2

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Nikolaos Sfikas

3

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Ana de Vera

4

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Gordon Francis

5

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Jeffrey Cohen

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

TRANSFORMS study group

7

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

8 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1704-1713

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

The measurement and clinical relevance of brain atrophy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Eight-year follow-up study of brain atrophy in patients with MS.

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Imaging outcomes for neuroprotection and repair in multiple sclerosis trials

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Magnetic resonance imaging measures of brain atrophy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Gray matter atrophy in multiple sclerosis: a longitudinal study

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Brain atrophy evolution and lesion load accrual in multiple sclerosis: a 2-year follow-up study.

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Regional brain changes in aging healthy adults: general trends, individual differences and modifiers

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve.

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes.

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Brain atrophy in multiple sclerosis: what we know and would like to know

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458514532317

21 January 2018

Identifiers

10.1177/1352458514532317

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39195628&oldid=2129458093"